Combined Technologies Create
Basis for Joint Development of Multi-Functional
Nanotechnology Platforms
EATONTOWN, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- American
CryoStem Corporation (OTCQB:CRYO), a biotechnology developer,
marketer and licensor of patented adipose tissue-based cellular
technologies for the Regenerative and Personalized Medicine
industries, today announced that the Company has filed its first
jointly-owned patent application with its research partners at
Rutgers University titled, "Nanoparticle-Mediated Synthetic
Transcription Factor for Enhanced Gene Regulation and Cell
Differentiation."
In May 2013, American CryoStem entered into a series of
agreements with research scientists at Rutgers, The State
University of New Jersey, including KiBum Lee, PhD, Professor of
Chemistry & Chemical Biology. American CryoStem's initial
collaboration with Dr. Lee, focused on utilizing American
CryoStem's proprietary ATCELL™ (Adipose-Derived Stem Cells (ADSCs))
and patented, ACSelerate™ (animal serum free), GMP grade, cell
culture and differentiation mediums to enhance Dr. Lee's
multi-functional nanotechnology and biomaterial platforms
(NanoScript™) that are capable of directing adipose-derived stem
cell differentiation. The combined technologies create a
Regenerative Medicine platform which can be used to treat a wide
range of degenerative diseases and orthopedic injuries.
NanoScript™ is a platform technology, based on the combination
of nanosized particles including gold and other unique FDA approved
biomaterials, with a series of predetermined peptides and binding
domains in specific ratios to create a synthetic transcription
factor capable of differentiating hADSCs without introducing a
virus or altering the cells DNA. NanoScript™ technology is
multi-functional and synergistic for use with the Company's
proprietary products to create any cell type including, but not
limited to; muscle, cartilage, bone, adipocyte, neural and induced
pluripotent cells (IPSCs) that are a genetic match for the donor.
The Company believes that this technology, to induce
differentiation without introducing a virus to the cell, provides
the Company an opportunity to create a series of cellular therapy
applications to treat chronic disease and traumatic injury, while
at the same time overcoming certain genetic hurdles associated
with generic cellular therapies.
"Rutgers University and Dr. Lee's extensive research experience
with nanotechnology-inspired stem cell differentiation
technologies, and their application of American CryoStem's
proprietary ATCELL™ and ACSelerate™ products, have served to
create a synergistic platform capable of dramatically increasing
targeted point-of-care delivery of specific regenerative medicine
therapies," stated Anthony Dudzinski, Chief Operating Officer
of American CryoStem.
"Our collaboration with American CryoStem has allowed us to
complete our ADSC-NanoScript technology platform and to advance our
research to produce the repeatable results necessary for clinical
development and FDA submission," stated Dr. Lee. Dr. Lee further
stated "The ability to work with an FDA-registered laboratory with
a unique and continuously expanding stem cell bank to ensure
quality, uniformity and cellular purity is key to creating our
master file for regulatory commercial product approval. The
ATCELL™ offering has greatly accelerated our platform technology
which will be described in a forthcoming white paper detailing our
ADSC-NanoScript research findings."
The initial focus of the Rutgers-American CryoStem collaboration
has been on the regeneration of muscle cells for the repair of
muscle loss from systemic disease and physical trauma, both of
which are large, under-satisfied, medical needs without a
repeatable cellular therapy solution. Further applications such as
nerve repair for systemic disease and traumatic injuries, which
markets the Company believes are underserved, are in the initial
stages of development.
John S. Arnone, CEO of American CryoStem, noted "Rutgers'
intellectual resources and extensive biotech research experience in
the field of Regenerative Medicine, coupled with our Company's
proprietary technologies and expertise with Adipose-Derived Stem
Cells, has given rise to a powerful combination of intellectual
property, skill, knowledge and common mission – to help accelerate
the translation of stem cell-based therapies to the markets and the
potential commercialization of exciting new stem cell therapies
capable of effectively treating human illnesses and diseases."
American CryoStem continues to pursue the scientific advancement
of multi-capable platforms with university-based research
collaborations; and at the same time, growing its intellectual
property pipeline while creating a wide range of cellular therapies
and treatments for a growing number of challenging and underserved
medical conditions and incurable diseases.
About KiBum Lee, PhD
Dr. Lee obtained his PhD in Chemistry from the Northwestern
University and completed his postdoctoral research in stem cell
biology at the Scripps Research Institute. His primary research
interest (http://chem.rutgers.edu/~kbleeweb/) is in developing and
integrating nanotechnologies and chemical functional genomics to
modulate signaling pathways in cells (e.g. stem cells and cancer
cells) towards specific cell lineages or behaviors.
About American CryoStem Corporation
A biotechnology pioneer in the fields of Regenerative and
Personalized Medicine, American CryoStem operates a
state-of-the-art, FDA-registered, clinical laboratory dedicated to
processing, bio-banking and development of cellular applications
using autologous adipose (fat) tissue and adipose derived stem
cells (ADSCs). Through its scientific efforts, the Company has
built a strong, strategic portfolio of intellectual property,
patent applications, and proprietary operating processes that form
its core standardized cellular platform. For more information,
please visit www.americancryostem.com and
www.acslaboratories.com. You can also find announcements and
press releases on our corporate Facebook, Twitter, and
LinkedIn profiles.
Forward Looking Statements
This press release may contain forward-looking statements,
including information about management's view of American CryoStem
Corporation's ("the Company") future expectations, plans and
prospects. In particular, when used in the preceding
discussion, the words "believes," "expects," "intends," "plans,"
"anticipates," or "may," and similar conditional expressions are
intended to identify forward-looking statements. Any
statements made in this press release other than those of
historical fact, about an action, event or development, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other factors, which may cause the
results of the Company, its subsidiaries and concepts to be
materially different than those expressed or implied in such
statements. Unknown or unpredictable factors also could have
material adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee
future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance
on these forward-looking statements. Finally, the Company
undertakes no obligation to update these statements after the date
of this release, except as required by law, and also takes no
obligation to update or correct information prepared by third
parties that are not paid for by American CryoStem Corporation.
CONTACT: Investor Relations Contact:
American CryoStem Corporation
Office: 732-747-1007
info@americancryostem.com
www.americancryostem.com
American Cryostem (CE) (USOTC:CRYO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
American Cryostem (CE) (USOTC:CRYO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024